Home » Topics » BioWorld Science

BioWorld Science
RSS

Radiosensitivity can be restored in advanced cancers

Nov. 15, 2019

New phase II trial evaluates KN-019 in rheumatoid arthritis

Nov. 14, 2019

Kiadis terminates development of ATIR-101, refocuses on NK-cell therapy platform

Nov. 14, 2019

Daiichi Sankyo opens enrollment for phase II study of valemetostat in relapsed/refractory ATL

Nov. 14, 2019

SQZ-PBMC-HPV begins phase I study in HPV+ recurrent, locally advanced or metastatic solid tumors

Nov. 14, 2019

Pivotal study of Nucala in hypereosinophilic syndrome meets primary endpoint

Nov. 14, 2019

Phase IIa study of THX-110 in obstructive sleep apnea meets primary endpoint

Nov. 14, 2019

Bacteriophage "cocktail" fights drinking sequelae, PSC

Nov. 14, 2019

Phase I/II study of DF-1001 in advanced HER2-expressing sold tumors begins dosing

Nov. 14, 2019

Sichuan Kelun-Biotech Biopharmaceutical identifies new arginase-1 inhibitors

Nov. 14, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...